IRC
ALNY icon

Investors Research Corp’s Alnylam Pharmaceuticals ALNY Stock Holding History

Investors Research Corp’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$602 Hold
2
– – ﹤0.01% 755
2026
Q1 		$662 Buy
+2
New +$681 ﹤0.01% 785
2020
Q2 		– Sell
-60
Closed -$7K – 1081
2020
Q1 		$7K Buy
+60
New +$6.93K ﹤0.01% 835

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Investors Research Corp's ALNY Position: Q2 2026 in Review

Investors Research Corp held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 2 shares worth $602. The position accounts for ﹤0.01% of the portfolio, ranked #755.

Investors Research Corp first reported a position in ALNY in Q1 2020 and has held it in 3 quarters since. The position peaked at $7K in Q1 2020. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Investors Research Corp held 2 shares of Alnylam Pharmaceuticals worth $602 as of Q2 2026.
  • Investors Research Corp left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Investors Research Corp's portfolio in Q2 2026, its #755 holding.
  • Investors Research Corp first reported a position in Alnylam Pharmaceuticals in Q1 2020 and has held it in 3 quarters since.
  • Investors Research Corp's Alnylam Pharmaceuticals position peaked at $7K in Q1 2020.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Investors Research Corp's 13F filing for Q2 2026, filed 10 Jul 2026.